Abstract
The increasing prevalence of type 2 diabetes mellitus is a major epidemiological, clinical, and economic issue. Good-quality treatment aimed at achieving normal blood sugar levels is essential in order to prevent complications.
Novel molecules (dapagliflozin, empagliflozin, imeglimin, liraglutide, omarigliptin, ranolazine, and sitagliptin) that have been introduced in the clinical practice in the recent years, or are going to be introduced, show a lower risk of hypoglycaemia, thus allowing superior prevention of late complications of type 2 diabetes.